NEW YORK ( TheStreet) -- Shares of ACADIA Pharmaceuticals (Nasdaq: ACAD) have taken a tremendous swing upward. The stock is trading at $2.71 as of 3:26 p.m. ET, 21% above Thursday's closing price of $2.24. Volume is at 2.2 million, five times the daily average of 442,100.

ACADIA has a market cap of $116.3 million and is part of the health care sector and drugs industry. Shares are up 60.8% year to date as of the close of trading on Thursday.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a P/E ratio of 5.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 16.7.

TheStreet Ratings rates ACADIA as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full ACADIA Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
null

If you liked this article you might like

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?